Gene and Immunotherapy of Neoplasms Affecting Human Communication

这个项目的目的是阐明 鳞状细胞癌的分子和免疫发病机制 上呼吸消化道，并使发展 这些疾病的分子和免疫治疗方法。 人和鼠鳞状细胞癌细胞系模型具有 已经被开发出来并用于识别基因， 使用分子和免疫学方法， 测定。促炎细胞因子，相关信号转导 途径分子和立即早期转录因子基因 已经显示在肿瘤中过度表达或被激活， 进展，并与积极的增长， 转移这些候选基因的功能如下： 过表达或通过转染肿瘤抑制 显性消极结构一直是最近的主题， 研究以确定分子和 免疫疗法 基于细胞因子 这些肿瘤产生的干扰免疫反应， 抗原识别和激活保护性免疫 重组和病毒治疗后的反应 转导的免疫调节细胞因子一直在进行中。的 用于免疫研究的第一个同基因小鼠口腔癌模型 该疗法是与来自美国的研究人员合作开发的。 路易斯维尔大学。这些研究导致了 三种具有抗肿瘤活性的细胞因子的鉴定。的 免疫的细胞机制和免疫的分子结构 识别的抗原将是未来研究的主题， 确定使用这些细胞因子的疗法或疫苗是否可以 适用于人体临床试验。

The purpose of this project is to elucidate the molecular and immune pathogenesis of squamous cell neoplasms of the upper aerodigestive tract, and to enable the development of approaches for molecular and immune therapy for these disorders. Human and murine squamous cell carcinoma cell line models have been developed and used to identify genes that are differentially expressed with tumor progression using molecular and immune assays. Proinflammatory cytokines, related signal transduction pathway molecules, and immediate early transcription factor genes have been shown to be overexpressed or activated with tumor progression, and are associated with aggressive growth and metastasis. The function of these candidate genes following overexpression or inhibition by transfection of tumors with dominant negative constructs has been the subject of recent investigations to identify potential targets for molecular and immune therapy. Based upon the hypothesis that the cytokines produced by these neoplasms disrupt the immune response, studies of antigen recognition and activation of protective immune responses following treatment with recombinant and virally transduced immunoregulatory cytokines have been ongoing. The first syngeneic murine model of oral carcinoma for study of immune therapy was developed in collaboration with investigators from the University of Louisville. These studies have resulted in the identification of three cytokines with anti-tumor activity. The cellular mechanisms of immunity and molecular structure of the antigens recognized will be the subject of future investigations to determine whether therapies or vaccines using these cytokines may be suitable for human clinical trials.